Irina Bancos1, Elizabeth Atkinson2, Charis Eng3, William F Young4, Hartmut P H Neumann5. 1. Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA. Electronic address: bancos.irina@mayo.edu. 2. Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. 3. Genomic Medicine Institute, Lerner Research Institute, and Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. 4. Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA. 5. Section for Preventive Medicine, Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany.
Abstract
BACKGROUND: Phaeochromocytoma or paraganglioma (collectively known as PPGL) in pregnant women can lead to severe complications and death due to associated catecholamine excess. We aimed to identify factors associated with maternal and fetal outcomes in women with PPGL during pregnancy. METHODS: We did a multicentre, retrospective study of patients with PPGL and pregnancy between Jan 1, 1980, and Dec 31, 2019, in the International Pheochromocytoma and Pregnancy Registry and a systematic review of studies published between Jan 1, 2005, and Dec 27, 2019 reporting on at least five cases. The inclusion criteria were pregnancy after 1980 and PPGL before or during pregnancy or within 12 months post partum. Eligible patients from the retrospective study and systematic review were included in the analysis. Outcomes of interest were maternal or fetal death and maternal severe cardiovascular complications of catecholamine excess. Potential variables associated with these outcomes were evaluated by logistic regression. FINDINGS: The systematic review identified seven studies (reporting on 63 pregnancies in 55 patients) that met the eligibility criteria and were of adequate quality. A further 197 pregnancies in 186 patients were identified in the International Pheochromocytoma and Pregnancy Registry. After excluding 11 pregnancies due to potential overlap, the final cohort included 249 pregnancies in 232 patients with PPGL. The diagnosis of PPGL was made before pregnancy in 37 (15%) pregnancies, during pregnancy in 134 (54%), and after delivery in 78 (31%). Of 144 patients evaluated for genetic predisposition for phaeochromocytoma, 95 (66%) were positive. Unrecognised PPGL during pregnancy (odds ratio 27·0; 95% CI 3·5-3473·1), abdominal or pelvic tumour location (11·3; 1·5-1440·5), and catecholamine excess at least ten-times the upper limit of the normal range (4·7; 1·8-13·8) were associated with adverse outcomes. For patients diagnosed during pregnancy, α-adrenergic blockade therapy was associated with fewer adverse outcomes (3·6; 1·1-13·2 for no α-adrenergic blockade vs α-adrenergic blockade), whereas surgery during pregnancy was not associated with better outcomes (0·9; 0·3-3·9 for no surgery vs surgery). INTERPRETATION: Unrecognised and untreated PPGL was associated with a substantially higher risk of either maternal or fetal complications. Appropriate case detection and counselling for premenopausal women at risk for PPGL could prevent adverse pregnancy-related outcomes. FUNDING: US National Institutes of Health.
BACKGROUND: Phaeochromocytoma or paraganglioma (collectively known as PPGL) in pregnant women can lead to severe complications and death due to associated catecholamine excess. We aimed to identify factors associated with maternal and fetal outcomes in women with PPGL during pregnancy. METHODS: We did a multicentre, retrospective study of patients with PPGL and pregnancy between Jan 1, 1980, and Dec 31, 2019, in the International Pheochromocytoma and Pregnancy Registry and a systematic review of studies published between Jan 1, 2005, and Dec 27, 2019 reporting on at least five cases. The inclusion criteria were pregnancy after 1980 and PPGL before or during pregnancy or within 12 months post partum. Eligible patients from the retrospective study and systematic review were included in the analysis. Outcomes of interest were maternal or fetal death and maternal severe cardiovascular complications of catecholamine excess. Potential variables associated with these outcomes were evaluated by logistic regression. FINDINGS: The systematic review identified seven studies (reporting on 63 pregnancies in 55 patients) that met the eligibility criteria and were of adequate quality. A further 197 pregnancies in 186 patients were identified in the International Pheochromocytoma and Pregnancy Registry. After excluding 11 pregnancies due to potential overlap, the final cohort included 249 pregnancies in 232 patients with PPGL. The diagnosis of PPGL was made before pregnancy in 37 (15%) pregnancies, during pregnancy in 134 (54%), and after delivery in 78 (31%). Of 144 patients evaluated for genetic predisposition for phaeochromocytoma, 95 (66%) were positive. Unrecognised PPGL during pregnancy (odds ratio 27·0; 95% CI 3·5-3473·1), abdominal or pelvic tumour location (11·3; 1·5-1440·5), and catecholamine excess at least ten-times the upper limit of the normal range (4·7; 1·8-13·8) were associated with adverse outcomes. For patients diagnosed during pregnancy, α-adrenergic blockade therapy was associated with fewer adverse outcomes (3·6; 1·1-13·2 for no α-adrenergic blockade vs α-adrenergic blockade), whereas surgery during pregnancy was not associated with better outcomes (0·9; 0·3-3·9 for no surgery vs surgery). INTERPRETATION: Unrecognised and untreated PPGL was associated with a substantially higher risk of either maternal or fetal complications. Appropriate case detection and counselling for premenopausal women at risk for PPGL could prevent adverse pregnancy-related outcomes. FUNDING: US National Institutes of Health.
Authors: Juan P Brito; Noor Asi; Irina Bancos; Michael R Gionfriddo; Claudia L Zeballos-Palacios; Aaron L Leppin; Chaitanya Undavalli; Zhen Wang; Juan P Domecq; Gabriela Prustsky; Tarig A Elraiyah; Larry J Prokop; Victor M Montori; Mohammad H Murad Journal: Clin Endocrinol (Oxf) Date: 2014-07-07 Impact factor: 3.478
Authors: Toby N Weingarten; Tasha L Welch; Tamara L Moore; Gulshat F Walters; Joni L Whipple; Alexandre Cavalcante; Irina Bancos; William F Young; Lucinda M Gruber; Muhammad Z Shah; Travis J McKenzie; Darrell R Schroeder; Juraj Sprung Journal: Urology Date: 2016-10-18 Impact factor: 2.649
Authors: Laurie A Wing; John V Conaglen; Goswin Y Meyer-Rochow; Marianne S Elston Journal: J Clin Endocrinol Metab Date: 2015-06-17 Impact factor: 5.958
Authors: Birke Bausch; Ulrich Wellner; Dirk Bausch; Francesca Schiavi; Marta Barontini; Gabriela Sanso; Martin K Walz; Mariola Peczkowska; Georges Weryha; Patrizia Dall'igna; Giovanni Cecchetto; Gianni Bisogno; Lars C Moeller; Detlef Bockenhauer; Attila Patocs; Karoly Rácz; Dmitry Zabolotnyi; Svetlana Yaremchuk; Iveta Dzivite-Krisane; Frederic Castinetti; David Taieb; Angelica Malinoc; Ernst von Dobschuetz; Jochen Roessler; Kurt W Schmid; Giuseppe Opocher; Charis Eng; Hartmut P H Neumann Journal: Endocr Relat Cancer Date: 2013-12-16 Impact factor: 5.678
Authors: Tobias Krauss; Alfonso Massimiliano Ferrara; Thera P Links; Ulrich Wellner; Irina Bancos; Andrey Kvachenyuk; Karina Villar Gómez de Las Heras; Marina Y Yukina; Roman Petrov; Garrett Bullivant; Laura von Duecker; Swati Jadhav; Ursula Ploeckinger; Staffan Welin; Camilla Schalin-Jäntti; Oliver Gimm; Marija Pfeifer; Joanne Ngeow; Kornelia Hasse-Lazar; Gabriela Sansó; Xiaoping Qi; M Umit Ugurlu; Rene E Diaz; Nelson Wohllk; Mariola Peczkowska; Jens Aberle; Delmar M Lourenço; Maria A A Pereira; Maria C B V Fragoso; Ana O Hoff; Madson Q Almeida; Alice H D Violante; Ana R P Quidute; Zhewei Zhang; Mònica Recasens; Luis Robles Díaz; Tada Kunavisarut; Taweesak Wannachalee; Sirinart Sirinvaravong; Eric Jonasch; Simona Grozinsky-Glasberg; Merav Fraenkel; Dmitry Beltsevich; Viacheslav I Egorov; Dirk Bausch; Matthias Schott; Nikolaus Tiling; Gianmaria Pennelli; Stefan Zschiedrich; Roland Därr; Juri Ruf; Timm Denecke; Karl-Heinrich Link; Stefania Zovato; Ernst von Dobschuetz; Svetlana Yaremchuk; Holger Amthauer; Özer Makay; Attila Patocs; Martin K Walz; Tobias B Huber; Jochen Seufert; Per Hellman; Raymond H Kim; Ekaterina Kuchinskaya; Francesca Schiavi; Angelica Malinoc; Nicole Reisch; Barbara Jarzab; Marta Barontini; Andrzej Januszewicz; Nalini Shah; William F Young; Giuseppe Opocher; Charis Eng; Hartmut P H Neumann; Birke Bausch Journal: Endocr Relat Cancer Date: 2018-05-10 Impact factor: 5.678